1. Please check and comment entries here.
Table of Contents


    3 Cycles of 177Lu-PSMA Therapy

    Subjects: Oncology
    View times: 27
    Submitted by: Sazan Rasul


    The [177Lu]Lu-PSMA radioligand therapy (PSMA-RLT) has emerged as a successful treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC). 

    1. Introduction

    Prostate cancer is one of the most common cancers and one of the leading oncologic causes of death in men in western countries. In these patients, particularly in those with aggressive, metastatic or castration-resistant prostate cancer (mCRPC), the levels of prostate-specific membrane antigen, also called glutamate carboxypeptidase type II and abbreviated as PSMA, are elevated up to 1000 times the normal value and are inversely correlated with the levels of androgens [1]. These receptors are a highly potent target in the diagnosis and treatment of patients with prostate tumors. Therefore, radionuclides targeting these peptides, such as [68Ga]Ga-PSMA-11 ligand positron emission tomography (68Ga-PSMA PET), which is widely applied as a non-invasive molecular method for imaging prostate cancer, and [177Lu]Lu-PSMA-617 radio-ligand therapy (PSMA-RLT), which has emerged as a valuable treatment in patients with mCRPC, are currently available. Although this novel therapy has not yet been approved for clinical use, it has been successfully administered to patients with mCRPC, based on the results of numerous studies [2][3][4][5]. Despite encouraging favorable outcomes of these trials on the efficacy and safety of PSMA-RLT [2][6], this therapy is presently used in mCRPC patients only as a last therapy option when other available standard medical procedures have failed to show clinical improvement. The therapeutic protocol in many centers, however, is quite heterogenous with treatments differing between two to six cycles of 3.7–9.3 GBq PSMA-RLT every 6 to 8 weeks [7]. Most recently, the TheraP study, a multicenter, unblinded, randomized phase 2 trial involving 11 centers in Australia, demonstrated a more frequent PSA response in mCRPC men treated with PSMA-RLT than in patients receiving cabazitaxel at the same stage of the disease. In addition, the results of this study reported fewer serious adverse events in men treated with PSMA-RLT than with cabazitaxel [8].

    2. Response Rate and Clinical Effects of Second PSMA-RLT Course

    The laboratory parameters of the entire studied mCRPC patients before and 1 month after the third last cycle of the second course of PSMA-RLT applied every 4 weeks have been compared. The PSA levels of the treated patients decreased significantly after three cycles of PSMA-RLT compared with baseline, median PSA 40.8 (range 0.87–1358 µg/L) vs. 20.2 (range 0.6–1926 µg/L), p = 0.002. Overall, 26 out of 43 (60.5%) patients demonstrated any decrease in PSA levels, 18 out of 43 (42%) had a PSA decline of ≥50%, and 8 of 43 (19%) patients showed a PSA decrease of ≥80%. The percentage of the PSA decline after both treatment courses of highly standardized PSMA-RLT, each three cycles with a 4-week interval, in all patients studied are depicted in Figure 1.
    Figure 1. Percentage of PSA change in the studied patients after two courses of the highly standardized PSMA-RLT, each three cycles with 4-week interval.
    Table 1. Comparison of laboratory parameters of the studied mCRPC patients before and after the second course of three cycles of PSMA-RLT every 4 weeks.
    Parameters Before Therapy After Therapy -Value
    * PSA µg/L 40.8 (0.87–1358) 20.2 (0.60–1962) 0.002
    Hemoglobin g/dL (mean ± SD) 11.5 ± 1.7 11 ± 1.6 0.006
    Thrombocyte g/L (mean ± SD) 208 ± 63 185 ± 63 0.002
    * Leucocyte g/L 5.4 (1.17–14.3) 4.8 (2.1–14.1) n.s.
    * Creatinine mg/dL 0.96 (0.54–2.24) 0.94 (0.61–2.6) n.s.
    * Alkaline phosphatase U/L 78 (42–995) 84 (47–1345) n.s.
    * LDH U/L 205 (96–278) 194 (86–551) n.s.
    PSA: prostate-specific antigen; LDH: lactate dehydrogenase; n.s.: not significant; (*) data not normally distributed, presented in median and range and log10 transferred for analysis.
    Moreover, levels of hemoglobin (Hb) (11.5 ± 1.7 g/dL vs. 11 ± 1.6 g/dL, p = 0.006) and platelets (208 ± 63 g/L vs. 185 ± 63 g/L, p = 0.002) one month after the third cycle were significantly lower compared to the baseline (Table 1). However, only two cases of grade 3 anemia and one case of grade 3 thrombocytopenia were observed among all the treated patients (Table 2). In addition, no statistically significant changes in the levels of leukocyte, creatinine, alkaline phosphatase, and lactate dehydrogenase were observed when we compared their basal values with those one month after treatment with three cycles of PSMA-RLT (Table 1). No patients with severe gastrointestinal adverse events, as well as no patients with acute parotitis and myelodysplastic syndrome, were reported during the second PSMA-RLT course.
    Table 2. Evaluation of treatment toxicities based on CTCAE version 4.0.
    Parameters Before Therapy After Therapy
    Toxicity (n) Toxicity (n)
    Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3
    Hemoglobin g/dL 18 7 0 15 9 2
    Thrombocyte g/L 8 0 0 8 0 1
    Leucocyte g/L 2 0 1 3 1 0
    Creatinine mg/dL 3 0 0 1 0 0
    (n): number of reported cases.

    This entry is adapted from 10.3390/cancers13102489


    1. Silver, D.A.; Pellicer, I.; Fair, W.R.; Heston, W.D.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 1997, 3, 81–85.
    2. Rasul, S.; Hacker, M.; Kretschmer-Chott, E.; Leisser, A.; Grubmuller, B.; Kramer, G.; Shariat, S.; Wadsak, W.; Mitterhauser, M.; Hartenbach, M.; et al. Clinical outcome of standardized (177)Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 713–720.
    3. Ahmadzadehfar, H.; Rahbar, K.; Kurpig, S.; Bogemann, M.; Claesener, M.; Eppard, E.; Gartner, F.; Rogenhofer, S.; Schafers, M.; Essler, M. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: A two-centre study. EJNMMI Res. 2015, 5, 114.
    4. Ahmadzadehfar, H.; Eppard, E.; Kurpig, S.; Fimmers, R.; Yordanova, A.; Schlenkhoff, C.D.; Gartner, F.; Rogenhofer, S.; Essler, M. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget 2016, 7, 12477–12488.
    5. McBean, R.; O’Kane, B.; Parsons, R.; Wong, D. Lu177-PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution. J. Med. Imaging Radiat. Oncol. 2019, 63, 538–545.
    6. Rahbar, K.; Boegemann, M.; Yordanova, A.; Eveslage, M.; Schafers, M.; Essler, M.; Ahmadzadehfar, H. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 12–19.
    7. Kratochwil, C.; Fendler, W.P.; Eiber, M.; Baum, R.; Bozkurt, M.F.; Czernin, J.; Delgado Bolton, R.C.; Ezziddin, S.; Forrer, F.; Hicks, R.J.; et al. EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT). Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 2536–2544.
    8. Hofman, M.S.; Emmett, L.; Sandhu, S.; Iravani, A.; Joshua, A.M.; Goh, J.C.; Pattison, D.A.; Tan, T.H.; Kirkwood, I.D.; Ng, S.; et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial. Lancet 2021, 397, 797–804.